Allurion Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15% Weight Loss

Rhea-AI Summary

Allurion Technologies (NYSE: ALUR) has published a study in Clinical Obesity showcasing the effectiveness of the Allurion Program for weight loss and body composition improvement. The study, involving 167 patients with an average BMI of 31.3, demonstrated:

- 15.7% average weight reduction at 4 months
- 17.1% average weight loss at 6 months
- 14.7% average weight loss maintained at 12 months

Notably, patients experienced a significant decrease in body fat percentage from 39% to 35.7% at 6 months, while preserving muscle mass. The study reported no serious adverse events, highlighting the safety and efficacy of the Allurion Balloon in achieving sustainable weight loss and improved body composition.

Positive

• Average weight reduction of 15.7% at 4 months, increasing to 17.1% at 6 months
• 94% weight loss maintenance 8 months after balloon passage
• Significant reduction in body fat percentage from 39% to 35.7% at 6 months
• Preservation of muscle mass during weight loss
• No serious adverse events reported, demonstrating safety of the Allurion Program

Negative

• None.

Insights

Medical Research Analyst

The study's findings are significant for Allurion Technologies, demonstrating the efficacy of their Allurion Program in achieving substantial weight loss while preserving muscle mass. Key points include:

• Average weight reduction of 15.7% at 4 months, peaking at 17.1% at 6 months
• 94% weight loss maintenance 8 months post-balloon passage
• Significant reduction in body fat percentage from 39% to 35.7%
• Preservation of muscle mass throughout the process

These results are particularly impressive given the challenge of maintaining weight loss post-intervention. The muscle mass preservation is crucial, as it helps maintain metabolic rate and overall health. The lack of serious adverse events also bolsters the safety profile of the Allurion Balloon. For investors, this data strengthens Allurion's position in the competitive obesity treatment market, potentially driving adoption rates and market share growth.

Market Research Analyst

This publication could significantly impact Allurion's market position. The obesity treatment market is projected to grow substantially and Allurion's non-surgical, effective solution addresses a critical need. Key market implications include:

• Differentiation from surgical alternatives, appealing to a broader patient base
• Potential for increased adoption by healthcare providers due to demonstrated efficacy and safety
• Opportunity for market expansion, given the 14.7% weight loss maintenance at 12 months
• Possible increase in patient confidence and word-of-mouth referrals

With a market cap of $45,597,353, Allurion is well-positioned to capitalize on these results. The data could drive partnerships with healthcare systems, insurance coverage negotiations and international market penetration. Investors should monitor how Allurion leverages this data for marketing and sales strategies, as it could significantly influence revenue growth and market valuation in the near to medium term.

In a study of 167 patients, average weight reduction was 15.7% at four months, 17.1% at six months, and 14.7% at one year

Body fat percentage decreased at six months with no change in muscle mass

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study in the journal Clinical Obesity on the impact of the Allurion Program on weight reduction and body composition.

The study evaluated weight loss and body composition changes for 167 patients with an average body mass index (BMI) of 31.3. After four months of balloon therapy, patients achieved an average weight reduction of 15.7%. Patients continued to lose weight after balloon passage, with an average weight loss of 17.1% at six months. At 12 months after balloon placement, the average weight loss was 14.7%, which demonstrates a 94% weight loss maintenance eight months after passage of the balloon.

Importantly, patients experienced significant reductions in body fat percentage, decreasing from 39% to 35.7% at six months, while muscle mass was preserved. No serious adverse events were reported.

“This study highlights that with proper preparation and follow-up, the Allurion Balloon provides safe and effective weight loss while maintaining muscle mass,” said Dr. Napoleón Salgado Macías, the study’s senior author. “With adherence to the Allurion Program’s lifestyle changes, individuals can achieve sustainable, long-term weight maintenance and significant improvements in body composition.”

The publication can be accessed by visiting https://onlinelibrary.wiley.com/doi/10.1111/cob.12705.

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight loss platform that features the Allurion Gastric Balloon, the world’s first and only swallowable, Procedure-less™ intragastric balloon for weight loss, and offers access to the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Coach Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The Allurion Gastric Balloon is an investigational device in the United States.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.

Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.

Forward-Looking Statements

This press release may contain certain forward-looking statements within the meaning of the U.S. federal and state securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions and include statements regarding the ability of the Allurion Balloon and the Allurion Program (including the VCS) , to improve patient outcomes, including with respect to weight reduction and maintenance and body composition changes. Forward-looking statements are predictions, projections and other statements about future events that reflect the current beliefs and assumptions of Allurion’s management based on information currently available to them and, as a result, are subject to risks and uncertainties. Many factors could cause actual future results or developments to differ materially from the forward-looking statements in this communication, including but not limited to (i) the ability of Allurion to obtain and maintain regulatory approvals for and successfully commercialize the Allurion Program, including the Allurion Balloon and the VCS, (ii) the timing of, and results from, our clinical studies and trials, (iii) the evolution of the markets in which Allurion competes, (iv) the ability of Allurion to defend its intellectual property, (v) the impact of the COVID-19 pandemic, the Russia and Ukraine war, and the conflict in the Middle East on Allurion’s business, (vi) Allurion’s expectations regarding its market opportunities, including those for the Allurion Program and VCS platform, and (vii) the risk of economic downturns and a changing regulatory landscape in the highly competitive industry in which Allurion operates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Allurion’s Annual Report on Form 10-K filed on March 26, 2024 (as subsequently amended) and other documents filed by Allurion from time to time with the U.S. Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Allurion assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Allurion does not give any assurance that it will achieve its expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241009928942/en/

Global Media

Cedric Damour

PR Manager

+33 7 84 21 02 20

cdamour@allurion.com

Investor

Mike Cavanaugh, Investor Relations

ICR Westwicke

(617) 877-9641

mike.cavanaugh@westwicke.com

Source: Allurion Technologies, Inc.

FAQ

What were the key findings of Allurion's (ALUR) weight loss study?

The study showed an average weight reduction of 15.7% at 4 months, 17.1% at 6 months, and 14.7% at 12 months. Patients experienced a decrease in body fat percentage from 39% to 35.7% at 6 months while preserving muscle mass.

How many patients were involved in Allurion's (ALUR) Clinical Obesity study?

The study evaluated weight loss and body composition changes for 167 patients with an average body mass index (BMI) of 31.3.

Did Allurion's (ALUR) weight loss program show long-term effectiveness?

Yes, the study demonstrated 94% weight loss maintenance eight months after the passage of the Allurion Balloon, with an average weight loss of 14.7% at 12 months after balloon placement.

Were there any serious side effects reported in Allurion's (ALUR) weight loss study?

No serious adverse events were reported in the study, highlighting the safety of the Allurion Program for weight loss.